Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial
By Doc LouallenRegenxbio shares advanced after the company said the first patient was dosed in its Phase IIb/III Naavigate study of surabgene lomparvovec for diabetic retinopathy and that it will receive a $100 million milestone payment from AbbVie.Shares were up 10% at $13.14 in midday trading Wed…